Enfortumab Vedotin + Pembrolizumab

Phase 2Recruiting

1 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Muscle-invasive Bladder Cancer

Conditions

Muscle-invasive Bladder Cancer

Trial Timeline

Mar 31, 2026 → Apr 30, 2031

NCT ID

NCT07475806

About Enfortumab Vedotin + Pembrolizumab

Enfortumab Vedotin + Pembrolizumab is a phase 2 stage product being developed by Astellas Pharma for Muscle-invasive Bladder Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07475806. Target conditions include Muscle-invasive Bladder Cancer.

What happened to similar drugs?

0 of 3 similar drugs in Muscle-invasive Bladder Cancer were approved

Approved (0) Terminated (0) Active (3)

🔄Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3

🔄Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3

🔄AtezolizumabRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07475806	Phase 2	Recruiting	Mar 31, 2026	Apr 30, 2031	Muscle-invasive Bladder Cancer
NCT06906822	Phase 2	Recruiting	Jun 10, 2025	Jun 1, 2028	Melanoma
NCT06809140	Phase 2	Recruiting	Apr 7, 2025	Nov 1, 2029	Muscle Invasive Bladder Urothelial Carcinoma
NCT06470282	Phase 1/2	Recruiting	Mar 31, 2025	Jan 31, 2028	Bladder Cancer
NCT05756569	Phase 2	Recruiting	Sep 26, 2023	Dec 16, 2027	Bladder Squamous Cell Carcinoma
NCT05239624	Phase 2	Recruiting	Jun 2, 2022	Jun 1, 2027	Urothelial Carcinoma
NCT04225117	Phase 2	Active	Mar 9, 2020	Sep 30, 2026	Locally Advanced or Metastatic Malignant Solid Tumors

Competing Products

12 competing products in Muscle-invasive Bladder Cancer

See all competitors

Product	Company	Stage	Hype Score
Pembrolizumab + Enfortumab Vedotin	Astellas Pharma	Phase 3	44
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)	AstraZeneca	Phase 3	44
Durvalumab (Imfinzi) + Tremelimumab	AstraZeneca	Phase 2	27
Pembrolizumab + Gemcitabine	Merck	Phase 2	39
Chemotherapy + Immunotherapy Induction + Immunotherapy Maintenance	Merck	Phase 2	42
Autogene Cevumeran + Nivolumab + Saline	Roche	Phase 2	42
Atezolizumab	Roche	Phase 3	44
Nivolumab + Nab-paclitaxel + Nivolumab	Bristol Myers Squibb	Phase 2	31
Cretostimogene Grenadenorepvec	CG Oncology	Phase 2	39
CG0070 + Nivolumab	CG Oncology	Phase 1	26
AU-011	Aura Biosciences	Phase 1	26
REOLYSIN® + Gemcitabine + Cisplatin	Oncolytics Biotech	Phase 1	11